ORIGINAL PAPER
The circulating inflammatory profile and tumour localisation in patients with pancreatic cancer
1
2nd Clinical Department of General and Gastroenterological Surgery, Medical University of Bialystok, Bialystok, Poland
2
Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland
3
Department of Hygiene, Epidemiology, and Ergonomics, Medical University of Bialystok, Bialystok, Poland
Submission date: 2023-11-21
Final revision date: 2023-12-10
Acceptance date: 2024-05-15
Publication date: 2024-06-29
Corresponding author
Przemysław Kostro
Przemysław Kostro 2nd Clinical Department of General and Gastroenterological Surgery Medical University of Bialystok Bialystok 15-276, Poland
Przemysław Kostro 2nd Clinical Department of General and Gastroenterological Surgery Medical University of Bialystok Bialystok 15-276, Poland
Medical Studies 2024;40(2):170-186
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Pancreatic cancer represents one of the greatest challenges in oncology. It is often diagnosed at a stage when treatment options are already limited. Inflammation is one of the key factors influencing the dynamics of pancreatic cancer development and progression.
Aim of the research:
The aim of this study is to assess the relationship between the location of pancreatic cancer and the levels of selected inflammatory cytokines, and to examine the differences in the concentration of these cytokines depending on the location of the tumour. We also assessed the diagnostic utility of inflammatory cytokines by conducting ROC curve analysis, as well as the correlations of cytokines with selected clinicopathological parameters and with the results of selected laboratory tests.
Material and methods:
Concentrations of 37 cytokines: CTACK, eotaxin, basic FGF, G-CSF, GRO-, HGF, IL-1, IL-1ra, IL-2R, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-16, IL-17, IL-18, IP-10, LIF, MCP-1, M-CSF, MIF, MIG, MIP-1, MIP-1, -NGF, PDGF-BB, RANTES, SCF, SCGF-, SDF-1, TNF-, TNF-, and TRIAL was measured in the venous blood of 42 patients with pancreatic cancer.
Results:
Eotaxin levels (p = 0.002), basic FGF (p = 0.316), G-CSF (p = 0.0408), IL-2R (p = 0.0487), IL-6 (p = 0.0001), IL-9 (p = 0.0002), IL-17 (p = 0.0153), IP-10 (p = 0.0228), MIP-1 (p = 0.0117), MIP-1 (p = 0.0021), RANTES (p = 0.0228), SCGF- (p = 0.223), TNF- (p = 0.0398), TNF- (p = 0.002) was statistically significantly higher in the patient group with tumours located in the head compared to patients with tumours in the body and tail of the pancreas. ROC analysis demonstrated that cytokines may be useful in differentiating the location of pancreatic cancer. There is a correlation between cytokine concentrations and the location of pancreatic cancer.
Conclusions:
Cytokines such as FGF, G-CSF, IL-2R, IL-6, IL-9, IL-17, IP-10, MIP-1, MIP-1, RANTES, SCGF-, TNF-, and TNF- differentiate patients with cancer located in the head of the pancreas from patients with a distal location of this cancer with a high degree of sensitivity and specificity.
Pancreatic cancer represents one of the greatest challenges in oncology. It is often diagnosed at a stage when treatment options are already limited. Inflammation is one of the key factors influencing the dynamics of pancreatic cancer development and progression.
Aim of the research:
The aim of this study is to assess the relationship between the location of pancreatic cancer and the levels of selected inflammatory cytokines, and to examine the differences in the concentration of these cytokines depending on the location of the tumour. We also assessed the diagnostic utility of inflammatory cytokines by conducting ROC curve analysis, as well as the correlations of cytokines with selected clinicopathological parameters and with the results of selected laboratory tests.
Material and methods:
Concentrations of 37 cytokines: CTACK, eotaxin, basic FGF, G-CSF, GRO-, HGF, IL-1, IL-1ra, IL-2R, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-16, IL-17, IL-18, IP-10, LIF, MCP-1, M-CSF, MIF, MIG, MIP-1, MIP-1, -NGF, PDGF-BB, RANTES, SCF, SCGF-, SDF-1, TNF-, TNF-, and TRIAL was measured in the venous blood of 42 patients with pancreatic cancer.
Results:
Eotaxin levels (p = 0.002), basic FGF (p = 0.316), G-CSF (p = 0.0408), IL-2R (p = 0.0487), IL-6 (p = 0.0001), IL-9 (p = 0.0002), IL-17 (p = 0.0153), IP-10 (p = 0.0228), MIP-1 (p = 0.0117), MIP-1 (p = 0.0021), RANTES (p = 0.0228), SCGF- (p = 0.223), TNF- (p = 0.0398), TNF- (p = 0.002) was statistically significantly higher in the patient group with tumours located in the head compared to patients with tumours in the body and tail of the pancreas. ROC analysis demonstrated that cytokines may be useful in differentiating the location of pancreatic cancer. There is a correlation between cytokine concentrations and the location of pancreatic cancer.
Conclusions:
Cytokines such as FGF, G-CSF, IL-2R, IL-6, IL-9, IL-17, IP-10, MIP-1, MIP-1, RANTES, SCGF-, TNF-, and TNF- differentiate patients with cancer located in the head of the pancreas from patients with a distal location of this cancer with a high degree of sensitivity and specificity.
REFERENCES (61)
1.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, KhemissaAkouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011 May; 364(19): 1817-1825.
2.
Rahim Moossa A, Lewis MH, Mackie CR. Surgical treatment of pancreatic cancer. Pol J Surg. 2018 Apr; 90(2): 45-53.
3.
Kowalska M, Kamocki Z. Body composition of patients suffering from pancreatic cancer. Pol J Surg. 2022 May; 95(1): 1-5.
4.
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Al- len JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center Experience. Oncologist. 2013 May; 18(5): 543-548.
5.
Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). [Internet]. 2008; 10(1): 58-62.
6.
Klotz R, Larmann J, Klose C, Bruckner T, Benner L, Doerr-Harim C, Tenckhoff S, Lock JF, Brede EM, Salvia R, Pola- ti E, Köninger J, Schiff JH, Wittel UA, Hötzel A, Keck T, Nau C, Amati AL, Koch C, Eberl T, Zink M, Toma- zic A, Novak-Jankovic V, Hofer S, Diener MK, Wei- gand MA, Büchler MW, Knebel P; PAKMAN Trial Group. Gastrointestinal complications after pancreatoduodenectomy with epidural vs patient-controlled intravenous analgesia: a randomized clinical trial. JAMA Surg. 2020 Jul; 155(7): e200794.
7.
Kruger D, Yako YY, Devar J, Lahoud N, Smith M. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: enhancing diagnostic accuracy. PLoS One. 2019 Aug; 14(8): e0221169.
8.
Chatterjee S. Oxidative Stress, Inflammation, and Disease. Oxidative Stress and Biomaterials. Elsevier, Amsterdam 2016; 35-58.
9.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (1979). 2011 Mar; 331(6024): 1565-1570.
10.
Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021 Jul; 6(1): 263.
11.
Fan Y, Mao R, Yang J. NF-B and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013 Mar; 4(3): 176-185.
12.
Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019 Dec; 11(12): 2002.
13.
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011 May; 140(6): 1807-1816.e1.
14.
Bosman F, Carnerio F, Hruban R, Theise N. Summary for Policymakers. Climate Change 2013 – The Physical Science Basis. Intergovernmental Panel on Climate Change, Ed.; Cambridge University Press, Cambridge, UK 2010; 1-30.
15.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017 Mar; 67(2): 93-99.
16.
Luchini C, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin. 2016 Dec; 9(4): 547-560.
17.
McGuigan A, Kelly P, Turkington RC, Jones C, Cole- man HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov; 24(43): 4846-4861.
18.
Chari ST, Maitra A, Matrisian LM, Shrader EE, Wu BU, Kambadakone A, Zhao YQ, Kenner B, Rinaudo JAS, Srivastava S, Huang Y, Feng Z; Early Detection Initiative Consortium. Early detection initiative: a randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. Contemp Clin Trials. 2022 Feb; 113: 106659.
19.
Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019; 20(3): 676.
20.
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995 May; 273(20): 1605-1609.
21.
Bel’skaya LV, Loginova AI, Sarf EA. Pro-inflammatory and anti-inflammatory salivary cytokines in breast cancer: relationship with clinicopathological characteristics of the tumor. Curr Issues Mol Biol. 2022 Oct; 44(10): 4676.
22.
Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019 Feb; 20(3): 676.
23.
Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, Frei R, Garbani M, Globinska A, Hess L, Huitema C, Kubo T, Komlosi Z, Konieczna P, Kovacs N, Kucukse- zer UC, Meyer N, Morita H, Olzhausen J, O’Mahony L, Pezer M, Prati M, Rebane A, Rhyner C, Rinaldi A, Sokolowska M, Stanic B, Sugita K, Treis A, van de Veen W, Wan- ke K, Wawrzyniak M, Wawrzyniak P, Wirz OF, Zakzuk JS, Akdis CA. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor , and TNF-: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Oct; 138(4): 984-1010.
24.
Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 2014 Nov; 1843(11): 2563-2582.
25.
Kuol N, Stojanovska L, Apostolopoulos V, Nurgali K. Crosstalk between cancer and the neuro-immune system. J Neuroimmunol. 2018 Feb; 315: 15-23.
26.
Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2008 Oct; 295(4): 709-717.
27.
Yako YY, Brand M, Smith M, Kruger D. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: a preliminary report. Pancreatology. 2017 May; 17(3): 438-444.
28.
Watt J, Kocher HM. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoi- imunology 2013 Dec; 2(12): e26788.
29.
Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014 Feb; 40(1): 118-128.
30.
van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond). 2020 Aug; 134(16): 2091-2115.
31.
Talukdar R. Complications of ERCP. Best Pract Res Clin Gastroenterol. 2016 Oct; 30(5): 793-805.
32.
Herder C, Fćrch K, Carstensen-Kirberg M, Lowe GD, Haapakoski R, Witte DR, Brunner EJ, Roden M, Ta- bák AG, Kivimäki M, Vistisen D. Biomarkers of subclinical inflammation and increases in glycaemia, insulin resistance and beta-cell function in non-diabetic individuals: the Whitehall II study. Eur J Endocrinol. 2016 Nov; 175(5): 367-377.
33.
Oldfield L, Evans A, Rao RG, Jenkinson C, Purewal T, Psarelli EE, Menon U, Timms JF, Pereira SP, Ghaneh P, Greenhalf W, Halloran C, Costello E. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine. 2022 Jan; 75: 103802.
34.
Pop VV, Seicean A, Lupan I, Samasca G, Burz CC. IL-6 roles – molecular pathway and clinical implication in pancreatic cancer – a systemic review. Immunol Lett. 2017 Jan; 181: 45-50.
35.
Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014: 149185.
36.
Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M. Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro. Cancer Sci. 2018 Aug; 109(8): 2509-2519.
37.
Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, Hassenpflug M, Bunge H, von Ahn K, Brecht R, Mathes A, Maier C, Umansky V, Werner J, Bazhin AV. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: Importance of myeloid-derived suppressor cells. Oncoimmunology. 2015 Apr; 4(4); e998519.
38.
McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. Oncogenic kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014 May; 25(5): 621-637.
39.
Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Vilar E, Wang TC, Bai- ley JM, McAllister F. Immune cell production of interleukin 17 induces stem cell features of pancreatic intraepithelial neoplasia cells. Gastroenterology. 2018 Jul; 155(1): 210-223.e3.
40.
Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus P, Lom- berk G, Urrutia R, Closa D, Iovanna JL. IL17 functions through the novel REG3-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Res. 2015 Nov; 75(22): 4852-4862.
41.
Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci 2018 May; 19(5): 1442.
42.
Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008 Mar; 68(5): 1443-1450.
43.
Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer. 2014 May; 13(1): 114.
44.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr; 33(3): 266-270.
45.
van Manen L, Groen J V., Putter H, Vahrmeijer AL, Swijnenburg RJ, Bonsing BA, Mieog JSD. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers. 2020 Feb; 25(2): 186-193.
46.
Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T, Zhang N, Li B, Qu Q, He X. Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant. J Cancer. 2018 Apr; 9(10): 1804-1812.
47.
Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020 Dec; 10(1): 1332.
48.
Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011 Dec; 103(24): 1827-1839.
49.
Lanki M, Seppänen H, Mustonen H, Salmiheimo A, Stenman UH, Salmi M, Jalkanen S, Haglund C. Pancreatic cancer survival prediction via inflammatory serum markers. Cancer Immunol Immunother. 2022 Sep; 71(9): 2287-2292.
50.
Ceriolo P, Fausti V, Cinotti E, Bonadio S, Raffaghello L, Bianchi G, Orcioni GF, Fiocca R, Rongioletti F, Pistoia V, Borgonovo G. Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. World J Gastroenterol. 2016 Mar; 22(12): 3496-3501.
51.
Song J, Li A, Qian Y, Liu B, Lv L, Ye D, Sun X, Mao Y. Genetically predicted circulating levels of cytokines and the risk of cancer. Front Immunol. 2022 Jul; 13: 886144.
52.
Yang R, Zhu S, Pischke SE, Haugaa H, Zou X, Tonnes- sen TI. Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice. J Surg Res. 2018 Aug; 228: 14-19.
53.
Pavlidis ET, Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobil Pancr Dis Int. 2018 Feb; 17(1): 17-21.
54.
Parlesak A, Schaeckeler S, Moser L, Bode C. Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Crit Care Med. 2007 Oct; 35(10): 2367-2374.
55.
Chowdhury AH, Camara M, Martinez-Pomares L, Zaitoun AM, Eremin O, Aithal GP, Lobo DN. Immune dysfunction in patients with obstructive jaundice before and after endoscopic retrograde cholangiopancreatography. Clin Sci (Lond). 2016; 130(17): 1535-1544.
56.
Takagi K, Domagala P, Hartog H, van Eijck C, Groot Koerkamp B. Current evidence of nutritional therapy in pancreatoduodenectomy: systematic review of randomized controlled trials. Ann Gastroenterol Surg. 2019 Nov; 3(6): 620-629.
57.
Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002 Jun; 122(7): 1763-1770.
58.
Furukawa A, Furukawa K, Suzuki D, Yoshitomi H, Takayashiki T, Kuboki S, Miyazaki M, Ohtsuka M. Effect of immunonutrition on infectious complications in low skeletal muscle mass patients after pancreaticoduodenectomy. Clin Nutr. 2021 Jan; 40(1): 103-109.
59.
Hamza N, Darwish A, O’Reilly DA, Denton J, Sheen AJ, Chang D, Sherlock DJ, Ammori BJ. Perioperative enteral immunonutrition modulates systemic and mucosal immunity and the inflammatory response in patients with periampullary cancer scheduled for pancreaticoduodenectomy: a randomized clinical trial. Pancreas. 2015 Jan; 44(1): 41-52.
60.
Shirakawa H, Kinoshita T, Gotohda N, Takahashi S, Nakagohri T, Konishi M. Compliance with and effects of preoperative immunonutrition in patients undergoing pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2012 May; 19(3): 249-258.
61.
Tumas J, Jasiūnas E, Strupas K, Šileikis A. Effects of immunonutrition on comprehensive complication index in patients undergoing pancreatoduodenectomy. Medicina 2020 Jan; 56(2): 52.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
